Avanza Fonder AB Has $14.02 Million Stake in Gilead Sciences, Inc. $GILD

Key Points

• Avanza Fonder AB increased its holdings in Gilead Sciences by 5.7% in Q2, now owning 126,465 shares valued at approximately $14.02 million.
• Gilead Sciences received multiple rating upgrades from analysts, including a boost from "hold" to "buy" from Truist Financial, with a new price target of $127.00.
• The company also announced a quarterly dividend of $0.79 per share, representing a 2.8% yield, set to be paid on September 29th to shareholders of record as of September 15th.

Avanza Fonder AB increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 126,465 shares of the biopharmaceutical company's stock after acquiring an additional 6,804 shares during the period. Avanza Fonder AB's holdings in Gilead Sciences were worth $14,021,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of GILD. Brighton Jones LLC boosted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $215,000. Fourth Dimension Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $54,000. Sunbelt Securities Inc. grew its holdings in shares of Gilead Sciences by 6.2% in the 4th quarter. Sunbelt Securities Inc. now owns 16,680 shares of the biopharmaceutical company's stock worth $1,535,000 after acquiring an additional 977 shares during the last quarter. Finally, Twin Lakes Capital Management LLC raised its position in shares of Gilead Sciences by 0.6% during the fourth quarter. Twin Lakes Capital Management LLC now owns 75,296 shares of the biopharmaceutical company's stock worth $6,955,000 after purchasing an additional 426 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $2.84 during midday trading on Tuesday, hitting $115.33. The company's stock had a trading volume of 3,704,908 shares, compared to its average volume of 8,065,160. The stock has a market capitalization of $143.10 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 0.77 and a beta of 0.36. The stock's 50 day simple moving average is $114.11 and its 200 day simple moving average is $109.95. Gilead Sciences, Inc. has a fifty-two week low of $81.83 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the business posted $2.01 EPS. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. Finally, Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,390,030 in the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.